This is a preview of subscription content, log in via an institution to check access.
References
Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands—the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8:311–31.
Deroose CM, Hindie E, Kebebew E, Goichot B, Pacak K, Taieb D, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57:1949–56.
Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, et al. A novel facile method of labeling octreotide with 18F-fluorine. J Nucl Med. 2010;51:454–61.
Long T, Yang N, Zhou M, Chen D, Li Y, Li J, et al. Clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms. Clin Nucl Med. 2019;44:452–8.
Acknowledgements
This research was funded by the project from “Kom op tegen Kanker”: “PET/MR imaging of the norepinephrine transporter and somatostatin receptor in neural crest and neuroendocrine tumors for better radionuclide therapy selection” and received support from Research Foundation – Flanders (FWO) (G0D8817N). Frederik Cleeren is a Postdoctoral Fellow of FWO (12R3119N). Christophe M. Deroose and Koen Van Laere are Senior Clinical Investigators at FWO.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Eric Van Cutsem has received research grants and personal fees for consultancy from Amgen, Bayer, Boehringer Ingelheim, Celgene, Ipsen, Lilly, Roche, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche and Servier. Chris Verslype has received research grants and performed consultancy services for Novartis and Ipsen. Koen Van Laere has performed consultancy services and contract research through KU Leuven for GE Healthcare, Merck, Janssen Pharmaceuticals, UCB, Syndesi Therapeutics and Eikonizo. Guy Bormans has performed funded contract research with Eikonizo, Merck, Celgene, Janssen Pharmaceuticals and UCB. Christophe M. Deroose has been a consultant for Novartis, Terumo, AAA, Ipsen, Sirtex, and Bayer outside the scope of the submitted work. There are no other conflicts of interest.
Ethical approval
All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Ethische Commissie Onderzoek UZ/KU Leuven S61727) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the prospective clinical study (NCT03883776), including the patient presented in this case report. A separate consent from the patient was obtained for publication of the case report.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Image of the Month.
Rights and permissions
About this article
Cite this article
Pauwels, E., Cleeren, F., Tshibangu, T. et al. Al18F-NOTA-octreotide: first comparison with 68Ga-DOTATATE in a neuroendocrine tumour patient. Eur J Nucl Med Mol Imaging 46, 2398–2399 (2019). https://doi.org/10.1007/s00259-019-04425-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-019-04425-1